Conversion from Cyclosporine to Tacrolimus improves Renal Function and Lipid Profile after Cardiac Transplantation
Miroslaw Garlicki, Pawel Czub, Krzysztof Labus, Marek P Ehrlich, Hanna RdzanekAnn Transplant 2006; 11(1): 24-27 :: ID: 496936
Abstract
Background: Calcineurin inhibitors (CNIs) have become the cornerstone of immunosuppressive regimens following heart transplantation, but their use is associated with nephrotoxicity. The impact on renal function after conversion from cyclosporine (CsA) to tacrolimus (TAC) is reported. Patients and methods: Fifteen patients (men age 42±11 years) after cardiac transplantation (HTX) were switched from CsA to TAC (mean time after HTX 21±6 month). There were 13 male and 2 female patients. Mean cholesterol and LDL level at the time of conversion were 217±65 ml/dl and and 136±51 mg/100ml respectively. Indication for HTX was ischemic cardiomyopathy (CMP) in 8, congenital in 3 and dilatative CMP in the remaining 4 patients. Results: Mean tacrolimus level (μg/dl) at 1, 3, 6 and 12 months were 8.6±3.3, 8.6±1.4, 9.2±2.8 and 9.8±2.5 respectively. There was a statistically significant improvement in creatinine levels at 1, 3, 6 and 12 months after conversion from baseline 1.9±0.7mg/dl to 1.4±0,5 mg/dl, 1.4±0.4 mg/dl, 1.3±0.4 mg/dl and 1.2±0.4 mg/dl, respectively (p< 0.05). Furthermore, TAC decreased cholesterol as well as LDL-levels during this one-year time frame. Conclusion: This study shows that conversion from CsA to tacrolimus after orthotopic heart transplantation improves renal function.
Keywords: Heart Transplantation, Renal Function, lipid profile
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860